Views Expressed Disclaimer:
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Highlights

  • Vir Biotechnology reported quarterly EPS of (USD 0.31).
  • Revenue rose 417.8% year over year to USD 64.07 million.
  • Shares closed at USD 7.43, down 1.72% for the session.

Vir Biotechnology (NASDAQ:VIR) announced quarterly earnings of (USD 0.31) per share. In the same quarter last year, the company reported earnings of (USD 0.76) per share.

Quarterly revenue totaled USD 64.07 million, compared with USD 19.91 million in the corresponding period a year earlier, representing a 417.8% year-over-year increase. Despite the higher revenue, the company reported a negative net margin of 2,963.54% and a negative return on equity of 50.76%.

Stock Performance Snapshot
Vir Biotechnology, closed at USD 7.43 on February 23. The stock declined USD 0.13, or 1.72%, during the trading session. The company’s market capitalization stands at approximately USD 1.03 billion.

Over the past five days, shares have slipped 1.85%, and they are down 1.72% over the past month. However, the stock has gained 69.63% in the last six months and is up 25.08% year to date. Over a one-year period, shares have declined 21.54%. Longer-term performance shows a 88.14% drop over five years and a 47.00% decline since inception.

Broker Consensus Signals Upside with Buy Rating
According to EODHD/Others data as of 24 Feb 2026, Analysts maintain a constructive outlook on VIR Biotechnology, Inc., with the current consensus recommendation at 1.8 (BUY). The average target price stands at USD 16.13, implying a substantial potential upside of approximately 117.09% from current levels.

While biotech investments inherently carry clinical and regulatory risks, the strong implied upside suggests brokers see meaningful value at current prices. Overall, sentiment indicates confidence in future growth prospects, supported by pipeline progress and strategic positioning within the biotechnology sector.

Business and Pipeline Focus
Vir Biotechnology is a clinical-stage immunology company developing treatments designed to prevent and address serious infectious diseases. The company employs proprietary technologies, including antibody isolation and screening platforms, cell-based assays, and bioinformatics systems to support its research efforts.

Its pipeline includes product candidates targeting influenza A, COVID-19, HIV, hepatitis B, and tuberculosis. The company’s strategy centers on utilizing monoclonal antibodies and immunomodulatory agents to engage the human immune response.

Vir Biotechnology reported a substantial year-over-year increase in quarterly revenue alongside improved earnings per share compared with the prior year’s quarter. While shares declined modestly following the announcement, performance trends over different time frames reflect both recent gains and longer-term declines as the company continues advancing its infectious disease programs.

FAQs

Q1. What were Vir Biotechnology’s quarterly earnings?
The company reported earnings of (USD 0.31) per share for the quarter.

Q2. How much revenue did Vir Biotechnology generate this quarter?
Quarterly revenue totaled USD 64.07 million, up significantly year over year.

Q3. What is Vir Biotechnology’s current market capitalization?
The company’s market capitalization is approximately USD 1.03 billion.